OXIS International, Inc. (OTCMKTS:OXIS) is a micro-cap name that’s clearly begun to spur some major interest among players in the marketplace as shares bounce up off recent lows in a move that looks every bit like a technical range breakout following Wednesday’s action. The extension was spurred on by OXIS’s announcement that four patients have been enrolled in the company’s Food and Drug Administration-approved (FDA) Phase 2 clinical trial of its promising cancer therapy, OXS-1550.
According to the release, Oxis Biotech, a wholly owned subsidiary of GT Biopharma, owns the worldwide rights to commercialize OXS-1550. The targeted immuno-oncology company is focused on novel antibody constructs that provide alternative treatments to cancer patients for whom existing therapies have failed.
OXIS International, Inc. (OTCMKTS:OXIS) frames itself as a company that, through its wholly owned subsidiary of Oxis Biotech, Inc., discovers, develops, and commercializes therapeutics from its proprietary product platform in various disease areas in the United States. The company is developing drugs focused on the treatment of cancer.
Its lead drug candidates include OXS-2175, a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer; OXS-4235, a small molecule therapeutic candidate to treat multiple myeloma and associated osteolytic lesion; and OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors.
OXIS was formerly known as DDI Pharmaceuticals, Inc. founded in 1965 and is based in Tampa, Florida.
According to company materials, “Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.”
Find out when $OXIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, OXIS shares have been on fire of late, with the stock’s latest breakout higher fueled by news that 4 patients have now been enrolled in the company’s phase 2 FDA trial for the OXS 1550 cancer asset.
According to the release, the Phase 1 trial of OXS-1550 was completed earlier this year to determine the safe and effective dose of the drug. The Phase 2 portion of the trial began in April and a total of 12 patients are expected to participate. Results of the Phase 2 trial are expected to be released in the first quarter of 2018.
Anthony Cataldo, Executive Chairman of GT Biopharma, said the enrollment of four patients in the Phase 2 trial is a key step for the company and a milestone for the promising technology. “The product performed well in Phase 1 studies of blood cancers and we look forward to providing a targeted immunotherapy product that has the capability of treating a number of different liquid tumors,” Mr. Cataldo said.
We’ve witnessed 81% tacked on to share pricing for the name in the past week, a bounce that has taken root amid largely bearish action over the larger time frame. This is emblematic of the stock. OXIS has evidenced sudden upward volatility on many prior occasions. Furthermore, the name has seen an influx in interest of late, with the stock’s recent average trading volume running topping 140% over what the stock has registered over the longer term.
Currently trading at a market capitalization of $5.21M, OXIS has a bankroll ($235K) of cash on the books, which must be weighed relative to about $11.8M in total current liabilities. The company is pre-revenue at this point. As more color becomes clear on the name, we will review the situation and update our take. For additional coverage on shares of $OXIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $OXIS, either long or short, and we have not been compensated for this article.